Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (109)	9/6/2002 7:55:27 PM
From: tuck	Read Replies (1) \| Respond to of 122

From the FDA's website: >>DATE AND TIME: September 25, 26, and 27, 8:00 a.m. LOCATION: Hilton, The Ballroom, 8727 Colesville Rd., Silver Spring, MD. CONTACT: Kathleen Reedy or LaNise Giles, Center for Drug Evaluation and Research, 301-827-7001. On September 25, the committee will discuss appropriate designs for clinical trials of new osteoporosis treatments. On September 26, the committee will discuss the safety and efficacy of biologic licensing application BL 103979, FABRAZYME (agalsidase beta, Genzyme Corp.) for the treatment of Fabry's Disease. On September 27, the committee will discuss the safety and efficacy of biologic licensing application BL 103977, REPLAGAL (agalsidase alfa, Transkaryotic Therapies) for the treatment of Fabry's disease.<< Cheers, Tuck